Topics:
Genitourinary Cancers • Bladder Cancer • Medical Oncology • Journal Club ft. NEJM publications
Will you offer adjuvant nivolumab for high-risk muscle invasive bladder cancer based on results of Checkmate 274?
Do you think adjuvant nivolumab should be the new standard of care based on current CM274 DFS data? If OS turns out to be no different, will you still offer patients adjuvant nivolumab?
Answer from: Medical Oncologist at Academic Institution
Based on the results of CM274, I do discuss the use of adjuvant nivolumab in patients with high risk MIBC (pT3, pT4a, or pN+ and patients not eligible for or declined adjuvant cisplatin-based combination chemotherapy for patients who had not received neoadjuvant cisplatin based chemotherapy and ypT2...
Answer from: Medical Oncologist at Community Practice
Until overall survival is available, I would restrict this to PDL1+ patients. As is unfortunately typical, ITT and PDL1+ DFS were described, but not the PDL1- subgroup. When ITT HR is 0.7 and PDL1+ subgroup HR is 0.53, one should doubt whether a PDL1- subgroup would derive a statistically significan...
Comments
Medical Oncologist at Premier Hem and Onc Svcs
I will wait for the FDA approval to the indication...
I will wait for the FDA approval to the indication...
Medical Oncologist at University of Utah Huntsman Cancer Institute
FDA approved in August 2021.
FDA approved in August 2021.
Answer from: Medical Oncologist at Community Practice
I do not believe that universal use of adjuvant Nivolumab should be the new standard of care based on improved disease-free survival, however, I still believe that the CheckMate 274 data is compelling and that delaying time to recurrence is a meaningful outcome for patients. This is particularly the...
Thank you for your nice summary of the current lan...